Skip to the answer

Risankizumab-rzaa Injection

Risankizumab-rzaa is a targeted biologic injection used to treat moderate-to-severe plaque psoriasis, psoriatic arthritis, Crohn's disease, and ulcerative colitis.

Brand name Skyrizi
Drug class Interleukin-23 Antagonist
Rx Form 1
Dr. Brian Staiger, PharmD, BCPS
Reviewed by Last reviewed Jul 10, 2026 Content updated Oct 2, 2026
🧬 Where this information comes from Click to expand

The clinical label records used on this page are FDA-filed Structured Product Labeling (SPL) retrieved through openFDA. We identified 1 clinical label set within the page’s selected clinical scope after exact ingredient or ingredient-combination matching and applicable route/form matching. Forms, routes, brands, labelers, strengths, and NDC product-record counts are built separately from matching FDA National Drug Code Directory records. The linked DailyMed document is a representative official source for verification, not the page’s only clinical source. View the linked label on DailyMed →

✓No current FDA shortage listed · checked Oct 5, 2026
Risankizumab-rzaa Injection at a glance The quick version — the full detail is in the Patient Information Guide below.
Dr. Brian Staiger, PharmD, BCPS
The Pharmacist’s Take By · Clinical pharmacist · Written

Skyrizi (risankizumab-rzaa) is a lab-made antibody that calms inflammation by blocking IL-23, an immune signal, and treats moderate-to-severe plaque psoriasis, psoriatic arthritis, Crohn's disease and ulcerative colitis. On the U.S. market since about 2019, it is now one of the more widely used biologics, usually started after creams, light therapy or older medicines fall short. Most people tolerate it well, and the usual complaints are colds and sinus infections, headache, tiredness or a sore injection spot. Because it quiets part of the immune system, infection is the thing to watch, so expect a tuberculosis (TB) screen first and report fever, chills or a lingering cough promptly.

Clinical pearls

  • For Crohn's or ulcerative colitis, liver blood tests come before and during the IV start-up phase; report yellowing eyes.
  • Avoid live vaccines, such as the nasal flu spray, while on Skyrizi, and tell every prescriber and pharmacy you take it.
  • Children 6 to 9 need an adult to give the injection; those 10 and older may self-inject under supervision after training.
  • Everyday medicines like warfarin, omeprazole and metoprolol showed no meaningful interaction, but other biologics or immunosuppressants need a prescriber's review.
How we write & review this content — our editorial policy →
How you get itPrescription only
Comes asInjection
Earliest FDA record2019
Companies listing it with the FDA1
FDA label last updatedJun 26, 2026
FDA’s strongest warning (boxed)None on the label

Patient information guide A plain-language walkthrough of Risankizumab-rzaa Injection, written from its FDA label.

What Risankizumab-rzaa Injection is used for

▾

Risankizumab-rzaa (Skyrizi) injection is approved for several inflammatory conditions, with specific approvals depending on the patient's age, the route of administration, and the condition being treated.

  • Skyrizi treats moderate-to-severe plaque psoriasis in adults and children 6 years of age and older who are candidates for systemic therapy or phototherapy
  • Skyrizi treats active psoriatic arthritis in adults and children 6 years of age and older
  • Skyrizi (intravenous induction followed by subcutaneous maintenance) treats moderately to severely active Crohn's disease in adults
  • Skyrizi (intravenous induction followed by subcutaneous maintenance) treats moderately to severely active ulcerative colitis in adults
  • Skyrizi is not approved for Crohn's disease or ulcerative colitis in children — that has not been established

How Risankizumab-rzaa Injection works

▾

Risankizumab-rzaa is a humanized monoclonal antibody — a precisely engineered protein — that targets a specific immune messenger called IL-23. It locks onto the p19 subunit of IL-23 and prevents it from connecting with its receptor on immune cells. Normally, IL-23 acts like a fire alarm, signaling the immune system to release inflammatory chemicals. By blocking that signal, risankizumab-rzaa reduces the cascade of inflammation that drives conditions like plaque psoriasis, psoriatic arthritis, Crohn's disease, and ulcerative colitis.

Risankizumab-rzaa Injection dosage

▾

Skyrizi is always given by injection — either intravenously (into a vein, by a healthcare provider) or subcutaneously (under the skin). It is not taken by mouth, and food does not affect it.

  • For plaque psoriasis and psoriatic arthritis, Skyrizi is given as a subcutaneous injection at weeks 0 and 4, then approximately every 12 weeks. Pediatric dosing is weight-based.
  • For Crohn's disease, treatment starts with an IV infusion (given over at least 1 hour) at weeks 0, 4, and 8 in a clinical setting, then switches to a subcutaneous maintenance injection every 8 weeks starting at week 12.
  • For ulcerative colitis, treatment starts with an IV infusion (given over at least 2 hours) at weeks 0, 4, and 8, then switches to a subcutaneous maintenance injection every 8 weeks starting at week 12.
  • If you miss a dose, take it as soon as you remember and then return to your regular schedule.

Dosing details from the FDA-approved label

From the Risankizumab-rzaa Injection prescribing information (“Dosage and Administration”). Doses are set by your prescriber for your product, condition, kidney function and age — never change a dose on your own.

  • Moderate-to-Severe Plaque Psoriasis: Adults
    • 150 mg administered by subcutaneous injection at Week 0, Week 4, and every 12 weeks thereafter
  • Moderate-to-Severe Plaque Psoriasis: Pediatric Patients 6 Years of Age and Older weighing less than 40 kg
    • 55 mg administered by subcutaneous injection at Week 0, Week 4, and every 12 weeks thereafter
    • dose based on body weight less than 40 kg
  • Moderate-to-Severe Plaque Psoriasis: Pediatric Patients 6 Years of Age and Older weighing 40 kg or greater
    • 150 mg administered by subcutaneous injection at Week 0, Week 4, and every 12 weeks thereafter
    • dose based on body weight 40 kg or greater
  • Active Psoriatic Arthritis: Adults
    • 150 mg administered by subcutaneous injection at Week 0, Week 4, and every 12 weeks thereafter
    • may be given alone or in combination with non-biologic DMARDs
  • Active Psoriatic Arthritis: Pediatric Patients 6 Years of Age and Older weighing less than 40 kg
    • 55 mg administered by subcutaneous injection at Week 0, Week 4, and every 12 weeks thereafter
    • dose based on body weight less than 40 kg
  • Active Psoriatic Arthritis: Pediatric Patients 6 Years of Age and Older weighing 40 kg or greater
    • 150 mg administered by subcutaneous injection at Week 0, Week 4, and every 12 weeks thereafter
    • dose based on body weight 40 kg or greater
  • Moderately to Severely Active Crohn's Disease: Induction (adults)
    • 600 mg administered by intravenous infusion over a period of at least one hour at Week 0, Week 4, and Week 8
  • Moderately to Severely Active Crohn's Disease: Maintenance (adults)
    • 180 mg or 360 mg administered by subcutaneous injection at Week 12, and every 8 weeks thereafter
    • Use the lowest effective dosage needed to maintain therapeutic response
  • Moderately to Severely Active Ulcerative Colitis: Induction (adults)
    • 1,200 mg administered by intravenous infusion over a period of at least two hours at Week 0, Week 4, and Week 8
  • Moderately to Severely Active Ulcerative Colitis: Maintenance (adults)
    • 180 mg or 360 mg administered by subcutaneous injection at Week 12, and every 8 weeks thereafter
    • Use the lowest effective dosage needed to maintain therapeutic response
Read the label’s full dosing text

2 DOSAGE AND ADMINISTRATION For the treatment of moderately to severely active Crohn’s disease and ulcerative colitis: Obtain liver enzymes and bilirubin levels prior to initiating treatment with SKYRIZI. ( 2.1 , 5.4 ) Complete all age-appropriate vaccinations as recommended by current immunization guidelines ( 2.1 , 5.5 ) Recommended Dosage Moderate-to-Severe Plaque Psoriasis: Adults : 150 mg administered by subcutaneous injection at Week 0, Week 4, and every 12 weeks thereafter. ( 2.3 ) Pediatric P atients 6 Years of Age and Older : Patients weighing less than 40 kg: 55 mg administered by subcutaneous injection at Week 0, Week 4, and every 12 weeks thereafter. ( 2.3 ) Patients weighing 40 kg or greater: 150 mg administered by subcutaneous injection at Week 0, Week 4, and every 12 weeks thereafter. ( 2.3 ) Active Psoriatic Arthritis: Adults: 150 mg administered by subcutaneous injection at Week 0, Week 4, and every 12 weeks thereafter. ( 2.4 ) Pediatric Patients 6 Y ears of Age and Older: Patients weighing less than 40 kg: 55 mg administered by subcutaneous injection at Week 0, Week 4, and every 12 weeks thereafter. ( 2.4 ) Patients weighing 40 kg or greater: 150 mg administered by subcutaneous injection at Week 0, Week 4, and every 12 weeks thereafter. ( 2.4 ) SKYRIZI may be administered alone or in combination with non-biologic disease-modifying antirheumatic drugs (DMARDs). ( 2.4 ) Moderately to Severely Active Crohn’s Disease: The recommended induction dosage is 600 mg administered by intravenous infusion over at least one hour at Week 0, Week 4, and Week 8. The recommended maintenance dosage is 180 mg or 360 mg administered by subcutaneous injection at Week 12, and every 8 weeks thereafter. Use the lowest effective dosage to maintain therapeutic response. ( 2.6 ) Moderately to Severely Active Ulcerative Colitis: The recommended induction dosage is 1,200 mg administered by intravenous infusion over at least two hours at Week 0, Week 4, and Week 8. The recommended maintenance dosage is 180 mg or 360 mg administered by subcutaneous injection at Week 12, and every 8 weeks thereafter. Use the lowest effective dosage to maintain therapeutic response.

Excerpted — the section continues on the label. Read the full Dosage and Administration section on DailyMed →

Risankizumab-rzaa Injection side effects

▾

The most commonly reported side effects vary somewhat by condition but include:

Common side effects

  • Upper respiratory infections (cold, sinus, throat infections)
  • Headache
  • Fatigue or weakness
  • Injection site reactions (redness, swelling, pain, bruising)
  • Tinea (fungal skin) infections
  • Joint pain (arthralgia)
  • Fever
  • Abdominal pain

When to get medical help

  • Seek immediate care if you have signs of a serious allergic reaction: trouble breathing, swelling of the face or throat, hives, or a rapid heartbeat
  • Call your doctor right away if you develop signs of infection: fever, chills, persistent cough, painful urination, or wounds that won't heal
  • Tell your doctor if you have been exposed to or have a history of tuberculosis (TB) — screening is required before starting Skyrizi
  • Get medical help right away if you notice signs of liver problems: yellowing of the skin or eyes, dark urine, severe fatigue, or upper right stomach pain
  • Do not receive live vaccines while on Skyrizi — tell all healthcare providers you are on this medication

Serious reactions to watch for and act on immediately include signs of a severe allergic reaction (trouble breathing, facial swelling), signs of infection (high fever, chills, persistent cough), and signs of liver problems (yellowing of skin or eyes, dark urine, severe upper right belly pain).

Risankizumab-rzaa Injection warnings and precautions

▾

Because Skyrizi dampens part of the immune system, it can increase your risk of infections — including serious ones like pneumonia, cellulitis (skin infection), and tuberculosis (TB). Your doctor will test you for TB before you start treatment and will ask you to report any signs of infection right away. Treatment should not begin if you have an active, significant infection.

  • Serious allergic reactions (including anaphylaxis) have occurred — get emergency help immediately if you have trouble breathing, throat tightening, or severe swelling
  • Liver injury has been reported, particularly during IV induction treatment for Crohn's disease and ulcerative colitis — liver enzyme tests are required before and during early treatment
  • Tuberculosis screening is required before starting Skyrizi; do not use if you have active TB
  • Live vaccines must be avoided during treatment — complete recommended vaccinations before starting Skyrizi

Risankizumab-rzaa Injection interactions

▾

Skyrizi has a limited drug interaction profile, but there are important points to know before starting it alongside other treatments.

  • Live vaccines — should not be given while on Skyrizi; the immune-suppressing effect could cause serious infection from the vaccine itself
  • Common liver-processed drugs (including warfarin, omeprazole, metoprolol, and midazolam) — clinical studies found no meaningful interaction with risankizumab-rzaa, but always tell your doctor about all medications you take
  • Other biologics or immunosuppressants — combining immune-modulating drugs increases infection risk; discuss all such medications with your prescriber

Not a complete list. The label covers the interactions the manufacturer studied or reported, and our own interaction database does not cover every medicine either. Bring your full medication list, including vitamins and herbal products, to your pharmacist.

🌿53 supplements and herbs with documented Risankizumab-rzaa Injection interactions, ranked by severity Check Risankizumab-rzaa Injection against a supplement or herb →

Before taking Risankizumab-rzaa Injection

▾
  • Serious allergy to risankizumab-rzaa or its ingredients — Skyrizi is contraindicated if you have had a serious hypersensitivity reaction to it before
  • Active infections — treatment should not start until any clinically significant active infection has resolved
  • Tuberculosis history — tell your doctor; TB screening is required, and anti-TB therapy may be recommended before starting
  • Crohn's disease or ulcerative colitis — liver enzyme and bilirubin blood tests are required before starting and during early (induction) treatment
  • Liver cirrhosis — your doctor should consider other treatment options if you have evidence of liver cirrhosis
  • Pregnancy — data on risankizumab-rzaa in pregnant women are limited; the drug may cross the placenta and could affect the baby's immune system; discuss the risks with your doctor and consider enrolling in the pregnancy registry (1-877-302-2161)
  • Breastfeeding — it is not known whether risankizumab-rzaa passes into human breast milk; discuss the benefits and risks with your doctor
  • Children under 6 years old — safety and effectiveness have not been established for any indication in this age group
  • Older adults (65+) — drug levels are comparable to younger adults; no dose adjustment is needed based on age alone

How your body processes Risankizumab-rzaa Injection

▾

When given as a subcutaneous injection, risankizumab-rzaa is well absorbed, with about 74–89% of the dose reaching the bloodstream. After a subcutaneous dose, peak blood levels are typically reached within 3 to 14 days. The drug stays in the body for a relatively long time — it has a half-life (the time for blood levels to fall by half) of approximately 21 to 28 days, which is why it can be dosed every 8 to 12 weeks during maintenance. Risankizumab-rzaa is broken down by the body the same way natural antibodies are — into small peptides and amino acids — rather than being processed by the liver's drug-metabolizing enzymes, which is why it has few interactions with other medications.

How to store Risankizumab-rzaa Injection

▾

Store in a refrigerator at 36°F to 46° F (2°C to 8°C). Do not freeze. Keep in the original cartons to protect from light.

Written from the FDA-approved label with AI and reviewed by our pharmacy team. How we use AI →

53

Supplements & herbs that interact with Risankizumab-rzaa Injection

53 supplements and herbal products have documented interactions with Risankizumab-rzaa Injection in the licensed clinical database we use. Most are manageable — but your pharmacist should know about everything you take, including vitamins and herbals.

Severity mix
  • Moderate · 52
  • Minor · 1
ACTIVE HEXOSE CORRELATED COMPOUND (AHCC) Moderate ALFALFA Moderate AMERICAN GINSENG Moderate ANDROGRAPHIS Moderate ASHWAGANDHA Moderate ASTRAGALUS Moderate BEE VENOM Moderate BETA-GLUCANS Moderate +45 more
Every supplement checked against Risankizumab-rzaa Injection — ranked by severity The full interaction hub: 52 moderate · 1 minor · every one linked to its full report. Check Risankizumab-rzaa Injection against your exact supplements

Educational information from a licensed clinical database (Natural Medicines) — see our data sources & update cadence. Not medical advice: an interaction being documented does not mean it will happen to you; do not start or stop medications or supplements without professional guidance.

Risankizumab-rzaa Injection: pharmacist answers to common questions

Quick, plain-English answers to the questions patients ask most about Risankizumab-rzaa Injection — the kind of thing our pharmacy team would talk through with you at the counter.

What conditions does Skyrizi treat?

▾
Skyrizi is approved for four conditions: moderate-to-severe plaque psoriasis, active psoriatic arthritis, moderately to severely active Crohn's disease, and moderately to severely active ulcerative colitis. For psoriasis and psoriatic arthritis, it's available for both adults and children aged 6 and older. For Crohn's disease and ulcerative colitis, it's currently approved only for adults.

How often do I need to take Skyrizi, and do I have to go to a clinic every time?

▾
That depends on what you're treating. For psoriasis or psoriatic arthritis, you get a subcutaneous (under-the-skin) injection at weeks 0 and 4, and then roughly every 12 weeks after that — and after proper training, adults can self-inject at home. For Crohn's disease or ulcerative colitis, the first three doses are IV infusions given in a clinic at weeks 0, 4, and 8. After that, you switch to subcutaneous injections every 8 weeks, which can potentially be done at home. Your care team will walk you through the process.

What side effects should I watch out for?

▾
The most common ones are upper respiratory infections (like colds or sinus infections), headache, fatigue, and reactions at the injection site like redness or soreness. Fungal skin infections and joint pain have also been reported. The more serious things to watch for are signs of a severe allergic reaction — difficulty breathing or swelling of the face — and signs of infection, like a high fever or a wound that won't heal. If any of those happen, get medical help right away.

Do I need any tests or shots before I start Skyrizi?

▾
Yes — your doctor will test you for tuberculosis (TB) before you start, since Skyrizi can lower your immune defenses. If you're starting it for Crohn's disease or ulcerative colitis, you'll also need liver enzyme blood tests before treatment begins. It's also important to get any recommended vaccinations up to date before starting, because live vaccines cannot be given while you're on Skyrizi.

Is it safe to take Skyrizi if I'm pregnant or breastfeeding?

▾
The honest answer is that we don't have enough data yet to be certain. Like other antibodies, risankizumab-rzaa can cross the placenta, which means your baby could be exposed to it, especially later in pregnancy. If you're pregnant or planning to become pregnant, talk to your doctor so you can weigh the risks and benefits together. A pregnancy registry is also available — your doctor can give you the details. For breastfeeding, it's not known whether the drug passes into breast milk, so this is another conversation to have with your healthcare provider.

Can my child use Skyrizi?

▾
Yes, for psoriasis and psoriatic arthritis — Skyrizi is approved for children 6 years and older for those conditions. The dose is based on your child's weight. For children ages 6 to 9, a parent or caregiver needs to give the injection; kids 10 and older can self-inject under adult supervision after training. Skyrizi has not been approved for Crohn's disease or ulcerative colitis in children — those uses are for adults only right now.

Is Risankizumab-rzaa Injection available over the counter?

▾
No. Risankizumab-rzaa Injection is a prescription medicine: every Risankizumab-rzaa Injection product listed with the FDA is prescription only, so it is not sold over the counter. Your prescriber decides whether it is appropriate for you, and your pharmacist dispenses it.

When was Risankizumab-rzaa Injection first available?

▾
The earliest FDA record we hold for Risankizumab-rzaa Injection is from 2019: its first approval in Drugs@FDA or its earliest product listing in the NDC Directory, whichever is older. Many older medicines were in use before their first formal FDA approval, so this is the earliest date on record, not necessarily when Risankizumab-rzaa Injection was first used.

Answers drafted from the FDA-approved label with AI and reviewed by our pharmacy team. How we use AI →

More about Risankizumab-rzaa Injection on HelloPharmacist

📊Risankizumab-rzaa Injection supplement interactions53 checked — ranked by severity 🌿Drug & Supplement CheckerRisankizumab-rzaa Injection vs. vitamins & herbs 💬Ask a PharmacistFree answer, usually < 24h 🔎NDC & pricing lookupFind Risankizumab-rzaa Injection NDCs & costs 🅰️Browse Drugs A–ZLook up any medication
Detailed data & references for Risankizumab-rzaa Injection Forms & strengths, pricing, billing codes, manufacturers, safety reports and sourcing — the data behind the page. Most people can stop here. Each section below opens on a tap.

Risankizumab-rzaa Injection forms and strengths (how it comes)

Risankizumab-rzaa Injection is available in 1 form. Different forms and brands can have different approved uses, doses, schedules, and directions. Follow the instructions for your exact product, and do not switch forms without guidance from your prescriber or pharmacist.

Injection

By injection · Into a vein · Under the skin
Brands Skyrizi
How this form is used
What it may be used for
  • Skyrizi subcutaneous injection is used to treat moderate-to-severe plaque psoriasis in adults and children 6 years and older
  • Skyrizi subcutaneous injection is used to treat active psoriatic arthritis in adults and children 6 years and older
  • Skyrizi intravenous infusion is used as the induction (starting) treatment for moderately to severely active Crohn's disease in adults, followed by subcutaneous maintenance injections
  • Skyrizi intravenous infusion is used as the induction treatment for moderately to severely active ulcerative colitis in adults, followed by subcutaneous maintenance injections
Important instructions
  • Skyrizi subcutaneous injections for psoriasis and psoriatic arthritis are given at week 0, week 4, and then roughly every 12 weeks; adults may self-inject after proper training, and children 6–9 require an adult to administer the dose
  • Skyrizi intravenous infusions for Crohn's disease or ulcerative colitis must be administered by a healthcare provider in a clinical setting and should not be mixed with other medications in the same IV line
  • Before injecting Skyrizi subcutaneously, allow the prefilled pen or syringe to reach room temperature out of direct sunlight; do not inject into skin that is tender, bruised, red, hardened, or affected by psoriasis
  • Skyrizi subcutaneous maintenance injections for Crohn's disease and ulcerative colitis are given starting at week 12 and then every 8 weeks; use the lowest effective dose to maintain your response
Available strengths 6 strengths
55 mg/0.37 mL 60 mg/mL 150 mg/mL 180 mg/1.2 mL 360 mg/2.4 mL 600 mg/10 mL
32 FDA-listed product records ⓘ

Risankizumab-rzaa Injection on the U.S. market: products, makers and brands

How Risankizumab-rzaa Injection appears in the FDA’s National Drug Code Directory — including its dosage forms, strengths, brand names, manufacturers, and FDA-listed product records. These are directory records, not sales or prescription volume.

1 company lists 8 Risankizumab-rzaa Injection product records with the FDA, mostly as injection; the earliest marketing or approval year on record is 2019. Brand names on the directory include Skyrizi; the rest are generics.

1
Dose forms ⓘ
1
Labelers (makers, repackagers, distributors)
1
Brand names
8
FDA-listed product records ⓘ
2019
Earliest FDA record ⓘ

Also listed with the FDA, not a patient dose form: Kit (8) — bulk drug substance sold to compounders/manufacturers and multi-item kits. These aren’t counted in the dose-form total above.

How widely Risankizumab-rzaa Injection is used (Medicaid data)

A general measure of how commonly Risankizumab-rzaa Injection is prescribed, based on Medicaid — one of the largest public drug programs. The figure below is prescriptions filled in Q1–Q4 2025, summed across every form and brand of the drug.

Think of this as a proxy for how widely Risankizumab-rzaa Injection is used, drawn from freely available public data. Medicaid is just one program — these numbers don’t include Medicare, other government coverage, or commercial and cash-pay prescriptions, so real-world use is higher than what’s shown here.

82,904
Medicaid prescriptions filled (Q1–Q4 2025)
$1.69B gross Medicaid reimbursement (before mandatory rebates — net cost is lower)

How commonly is Risankizumab-rzaa Injection prescribed? Of the 1,601 medications we measure, Risankizumab-rzaa Injection ranks #538 by Medicaid prescriptions — more than 66% of them.

Where Risankizumab-rzaa Injection ranks among the drugs we measure · Q1–Q4 2025 · neighbors ±5
Total prescriptions — #538 of 1,601
#533 Gentamicin Ophthalmic 84,328 Rx #534 Ruxolitinib 84,308 Rx #535 Vibegron 84,266 Rx #536 Valbenazine 83,640 Rx #537 Colestipol 83,276 Rx #538 Risankizumab-rzaa Inje... 82,904 Rx #539 Flecainide 82,857 Rx #540 Ethosuximide 82,457 Rx #541 Cabotegravir 81,731 Rx #542 Finerenone 81,262 Rx #543 Calcium Acetate 81,167 Rx

Utilization by Risankizumab-rzaa Injection product

Pick a product to see its own Medicaid numbers. Each chip is one clinical product — a specific strength & dosage form as defined by RxNorm — with brand-name and generic versions combined.

The 1 mL / 150 mg/mL auto-injector is the most-dispensed Risankizumab-rzaa Injection product — about 61% of these Medicaid prescriptions.

1 ML risankizumab-rzaa 150 MG/ML Auto-Injector Most dispensed

50,182 Medicaid prescriptions (Q1–Q4 2025) 61% of Risankizumab-rzaa Injection prescriptions shown $1.06B gross reimbursement (before rebates) ≈ $21,145 per prescription (gross)

Summed across the 1 of 2 listed NDC products with Medicaid activity — every brand and generic of this exact strength & form. RxNorm 2540692

2.4 ML risankizumab-rzaa 150 MG/ML Cartridge

19,927 Medicaid prescriptions (Q1–Q4 2025) 24% of Risankizumab-rzaa Injection prescriptions shown $425.7M gross reimbursement (before rebates) ≈ $21,365 per prescription (gross)

Summed across the 1 of 4 listed NDC products with Medicaid activity — every brand and generic of this exact strength & form. RxNorm 2604625

10 ML risankizumab-rzaa 60 MG/ML Injection

6,321 Medicaid prescriptions (Q1–Q4 2025) 8% of Risankizumab-rzaa Injection prescriptions shown $67.7M gross reimbursement (before rebates) ≈ $10,707 per prescription (gross)

Summed across the 1 of 2 listed NDC products with Medicaid activity — every brand and generic of this exact strength & form. RxNorm 2604618

1 ML risankizumab-rzaa 150 MG/ML Prefilled Syringe

4,859 Medicaid prescriptions (Q1–Q4 2025) 6% of Risankizumab-rzaa Injection prescriptions shown $102.8M gross reimbursement (before rebates) ≈ $21,154 per prescription (gross)

Summed across the 1 of 2 listed NDC products with Medicaid activity — every brand and generic of this exact strength & form. RxNorm 2540698

1.2 ML risankizumab-rzaa 150 MG/ML Cartridge

1,615 Medicaid prescriptions (Q1–Q4 2025) 2% of Risankizumab-rzaa Injection prescriptions shown $35M gross reimbursement (before rebates) ≈ $21,684 per prescription (gross)

Summed across the 1 of 4 listed NDC products with Medicaid activity — every brand and generic of this exact strength & form. RxNorm 2613758

Shares are of the Medicaid prescriptions shown here. Product grouping follows RxNorm (the National Library of Medicine’s drug terminology), so “one product” means one strength & dosage form regardless of manufacturer. Dollar figures are gross Medicaid reimbursement before mandatory rebates — rebates (often large, especially for brand-name drugs) are confidential, so actual net cost to Medicaid is lower than shown.

Source: Medicaid State Drug Utilization Data (CMS), aggregated by generic ingredient — summed across every NDC (all brands, strengths, salt forms and dosage forms) of Risankizumab-rzaa Injection, and across all states and both fee-for-service and managed-care claims. A general popularity signal; it excludes Medicare, commercial insurance and cash prescriptions, so it is not total U.S. use. Based on the 5 of 14 listed Risankizumab-rzaa Injection NDCs with Medicaid activity.

Compare Risankizumab-rzaa Injection products

A representative set of FDA-listed product records for Risankizumab-rzaa Injection — across manufacturers, strengths, and dosage forms, grouped by form with each product’s manufacturer and how the FDA approved it. The same medicine may be made and packaged by different companies, so a single drug can have many directory entries. (It’s also why a refill can look different — a new shape, color, or box — even though it contains the same medication.)

Strength Route Manufacturer / Labeler Category ⓘ Details
💊Injection
55 mg/0.37 mL Subcutaneous AbbVie Inc. BLA View NDC →
150 mg/mL Subcutaneous AbbVie Inc. × 2 listings BLA View NDC →
180 mg/1.2 mL Subcutaneous AbbVie Inc. × 2 listings BLA View NDC →
600 mg/10 mL Intravenous AbbVie Inc. BLA View NDC →
💊Kits
— Intravenous AbbVie Inc. × 2 listings BLA View NDC →

Showing 8 of 8 products — FDA National Drug Code Directory. See every product, package size and price: browse all 8 Risankizumab-rzaa Injection NDCs →

Risankizumab-rzaa Injection recall history

A recall is when a specific batch of a medicine is pulled from the market — usually a manufacturing issue, not a problem with the drug itself. Class I is most serious, Class III least.

The FDA’s enforcement reports list no Risankizumab-rzaa recalls since July 2021.

✅No Risankizumab-rzaa recalls on record since July 2021

Source: FDA enforcement (recall) reports, via openFDA; our copy was last updated Sep 24, 2026.

RxNorm Concept Web — From Ingredient to Every Form and Strength

This page starts with one ingredient concept (IN). The branches below show its dose-form concepts (SCDF), then the available clinical drug and strength concepts (SCD). Combination products remain separate concepts with their own pages.

Ingredient (IN) Risankizumab-rzaa Injection RxCUI 2166040 4 dose forms · 8 strengths

Look up RxCUI 2166040 in the RxCUI Atlas →

RxNorm is the U.S. National Library of Medicine’s normalized drug vocabulary. Its concept hierarchy can include forms that are not currently marketed; the status on each branch compares that concept with current FDA listings. RxCUIs identify vocabulary concepts, not individual packages or manufacturers.

💵 What Risankizumab-rzaa Injection costs pharmacies (NADAC benchmark)

The national average invoice price pharmacies pay for the drug itself, from CMS's NADAC survey (data as of Sep 30, 2026). This is a supply-cost benchmark — not a retail price and not what you'd pay at the counter.

FormStrengthPharmacy acquisition benchmark
Injection · Subcutaneous 150 mg/mL $22,887.40 per mL NDC details & price history
Why show this? Your out-of-pocket cost depends on insurance, pharmacy markup, and discounts — but the acquisition benchmark tells you whether the medication itself is inexpensive or costly, which strengths cost more per dose, and whether a cash-price quote is in a reasonable range. Each row links to the NDC-level record with its full price history.

Source: CMS National Average Drug Acquisition Cost (NADAC), a survey of retail pharmacy invoice prices. Benchmarks shown are the range across package sizes of a representative product for each form and strength — other manufacturers' products may differ.

Risankizumab-rzaa Injection brand names

Risankizumab-rzaa Injection is sold under one brand name in the FDA directory — Skyrizi. A brand and its generic contain the same active ingredient; the brand name belongs to one company's product.

Skyrizi

Who makes Risankizumab-rzaa Injection: manufacturers and labelers

One company lists Risankizumab-rzaa Injection products with the FDA. By number of product records, the largest are AbbVie Inc.. Labelers include manufacturers and repackagers; the product in your bottle depends on which one your pharmacy stocks.

AbbVie Inc. 8

Risankizumab-rzaa Injection drug class (RxNorm)

Risankizumab-rzaa Injection belongs to the Interleukin-23 Antagonist class.

Pharmacologic class Interleukin-23 Antagonist
Drug family (ATC) Interleukin inhibitors
How it works Interleukin-23 Antagonists

Classified by RxNorm RxClass — the U.S. National Library of Medicine's standardized drug-classification service (Established Pharmacologic Class from the FDA, the ATC drug family from the WHO, and mechanism of action). Reference only, not medical advice.

Sources for this Risankizumab-rzaa Injection page

Core label, product, RxNorm, safety, and utilization data on this page come from the sources identified below. AI-written, editorial, and licensed sections are labeled separately.

📄
FDA-filed drug labels (SPL) Uses, dosing, warnings & side effects from SPL records retrieved through openFDA; the linked representative set can be verified on DailyMed. ✓ Linked label effective Jun 26, 2026
🏭
Forms, brands & labelersAggregated from ingredient-matched FDA National Drug Code Directory product records for Risankizumab-rzaa Injection.
📈
Real-world reportsThe FDA Adverse Event Reporting System (FAERS), served through openFDA.
🚨
Recalls & shortagesopenFDA drug-enforcement reports and the FDA drug-shortage database.
🧾 Clinical label set — FDA-filed SPL labels retained for Risankizumab-rzaa Injection after exact ingredient or ingredient-combination matching and applicable route/form matching
Clinical labels in scope
1
Finished products in the current FDA directory
8
Companies listing them (makers, repackagers, distributors)
1
FDA labeler codes behind them ⓘ
1
Linked representative label ⓘ
AbbVie Inc.
Linked label effective
Jun 26, 2026
Composite sections available
21
Linked SPL Set ID
7148c8eb-b39e-e20a-6494-a6df82392858
Linked SPL Document ID
ded2361a-2d22-4ee0-95f5-ff04c840dc42
Open the linked representative label on DailyMed ↗

How this page is built

HelloPharmacist combines public FDA and NLM records and does not author the underlying clinical facts. The plain-language sections are written with AI from the FDA-approved label text and reviewed by our pharmacy team before publication. AbbVie Inc. is the representative DailyMed label linked for verification and dates. This is general education, not medical advice: always talk to your doctor or pharmacist about your own medicines. How we build and review drug pages →